经典型骨肉瘤中NOTCH3和EZH2蛋白的表达及预后意义

Expression of NOTCH3 and EZH2 in conventional osteosarcoma and their prognostic significances

目的 探讨NOTCH3蛋白和EZH2蛋白在经典型骨肉瘤中的共同表达及其与临床病理学特征、预后的关系。方法 收集2012—2019本院初诊初治且有完整临床资料的经典型骨肉瘤病例43例,运用免疫组织化学EnVision法进行NOTCH3和EZH2蛋白的检测。结果 NOTCH3与EZH2蛋白双低表达19例(44.2%),双高表达7例(16.3%),其他17例(39.5%)。NOTCH3和EZH2的双高表达术后转移高于双低表达(P<0.05),且双高表达患者的总生存期和无进展生存期更短(P<0.05)。Cox多因素分析提示NOTCH3和EZH2的共同表达是独立的预后风险因素(P<0.05)。结论 经典型骨肉瘤中NOTCH3和EZH2蛋白的双高表达与术后转移和生存时间显著相关,可作为患者术后治疗和健康管理的有效依据。

Objective To explore the expression of NOTCH3 and EZH2 in osteosarcoma samples and their prognostic significances.Methods Forty-three cases of classic osteosarcoma encountered during the period from 2012-2019 were enrolled.Immunohistochemistry(EnVision method) was conducted in osteosarcoma samples,and then the results were statistically analyzed.Results NOTCH3 and EZH2 lowly expressed in 19 cases(44.2%),while both highly expressed in 7 cases,and one of them expressed in 17 cases(39.5%).High expression of NOTCH3 and EZH2 was correlated with tumor metastasis and mortality,which was also associated with shortened overall survival time and progression free survival time(P<0.05).NOTCH3 and EZH2 expression was an independent risk factor of osteosarcoma prognosis(P<0.05).Conclusion High expression of NOTCH3 and EZH2 is associated with malignant events in the development of osteosarcoma.NOTCH3 and EZH2 may be a prognostic biomarker for osteosarcoma.